CASI Pharmaceuticals Inc - Asset Resilience Ratio

Latest as of September 2025: 0.00%

CASI Pharmaceuticals Inc (CASI) has an Asset Resilience Ratio of 0.00% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Check strategic asset allocation of CASI Pharmaceuticals Inc to assess the company's strategic physical and investment asset allocation.

Liquid Assets

$0.00

Cash + Short-term Investments

Total Assets

$24.46 Million

All company assets

Resilience Assessment

Low

Financial Resilience Level

Asset Resilience Ratio Trend (2003–2024)

This chart shows how CASI Pharmaceuticals Inc's Asset Resilience Ratio has changed over time. See CASI equity financing ratio to measure how much of total assets are equity-financed.

Liquid Assets Composition Over Time

This chart breaks down CASI Pharmaceuticals Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see CASI Pharmaceuticals Inc market capitalisation.

Current Liquid Assets Breakdown

Component	Amount	% of Total Assets
Cash & Equivalents	$0.00	0%
Short-term Investments	$0.00	0%
Total Liquid Assets	$0.00	0.00%

Asset Resilience Insights

Limited Liquidity: CASI Pharmaceuticals Inc maintains only 0.00% of assets in liquid form.
This low level may indicate efficient asset utilization but could pose risks during economic downturns.
The company maintains a balanced mix of cash and short-term investments.

CASI Pharmaceuticals Inc Industry Peers by Asset Resilience Ratio

Compare CASI Pharmaceuticals Inc's asset resilience ratio with other companies in the same industry.

Company	Industry	Asset Resilience Ratio
Biomarin Pharmaceutical Inc NASDAQ:BMRN	Biotechnology	0.00%
Cyclacel Pharmaceuticals Inc NASDAQ:CYCC	Biotechnology	-55.36%
Krystal Biotech Inc NASDAQ:KRYS	Biotechnology	23.06%
Verona Pharma PLC ADR NASDAQ:VRNA	Biotechnology	0.00%
Centessa Pharmaceuticals PLC ADR NASDAQ:CNTA	Biotechnology	33.37%
Beijing Tiantan Biological Products Corp Ltd SHG:600161	Biotechnology	8.08%
Hebei Changshan Biochem Pharma SHE:300255	Biotechnology	-0.03%
BB Biotech AG SW:BION	Biotechnology	0.05%

Annual Asset Resilience Ratio for CASI Pharmaceuticals Inc (2003–2024)

The table below shows the annual Asset Resilience Ratio data for CASI Pharmaceuticals Inc.

Year	Asset Resilience Ratio (%)	Liquid Assets	Total Assets	Change
2024-12-31	4.89%	$2.62 Million	$53.67 Million	-13.30pp
2023-12-31	18.18%	$13.69 Million	$75.27 Million	+13.79pp
2022-12-31	4.39%	$4.22 Million	$96.23 Million	-2.74pp
2021-12-31	7.14%	$9.87 Million	$138.30 Million	-0.15pp
2020-12-31	7.29%	$9.31 Million	$127.73 Million	+6.68pp
2019-12-31	0.61%	$625.00K	$102.63 Million	-0.20pp
2018-12-31	0.80%	$912.20K	$113.41 Million	--
2017-12-31	0.00%	$0.00	$45.10 Million	--
2016-12-31	0.00%	$0.00	$27.71 Million	--
2015-12-31	0.00%	$0.00	$5.83 Million	--
2014-12-31	0.00%	$0.00	$11.31 Million	--
2013-12-31	0.00%	$0.00	$15.51 Million	--
2012-12-31	0.00%	$0.00	$8.98 Million	--
2011-12-31	0.00%	$0.00	$3.24 Million	--
2010-12-31	0.32%	$25.82K	$8.04 Million	-0.22pp
2009-12-31	0.54%	$54.07K	$10.07 Million	-25.56pp
2008-12-31	26.10%	$7.55 Million	$28.92 Million	-7.99pp
2007-12-31	34.09%	$18.07 Million	$53.01 Million	-19.17pp
2006-12-31	53.26%	$29.67 Million	$55.72 Million	+2.00pp
2005-12-31	51.26%	$18.67 Million	$36.43 Million	+15.44pp
2004-12-31	35.82%	$14.11 Million	$39.40 Million	+30.52pp
2003-12-31	5.30%	$2.13 Million	$40.15 Million	--

pp = percentage points

About CASI Pharmaceuticals Inc

NASDAQ:CASI USA Biotechnology

Market Cap

$4.99 Million

Market Cap Rank

#28875 Global

#5849 in USA

Share Price

$0.24

Change (1 day)

+17.06%

52-Week Range

$0.21 - $2.47

All Time High

$82.30